Letrozole Tablet, Film Coated
Product Images NDC 69117-0004

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 69117-0004). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Yiling Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (11005a48 13fd 4c6d A024 1e39e3528e45 01)

Figure-1 (11005a48 13fd 4c6d A024 1e39e3528e45 01)
FDA Label Image

Figure-2 (Figure 1 Disease Free Survival Median Follow Up 73 Months Itt Approach)

Figure-2 (Figure 1 Disease Free Survival Median Follow Up 73 Months Itt Approach)
This appears to be a tabular data on the effectiveness of two drugs, Letrozole and Tamoxifen, in treating some medical condition. The table compares the number of patients, events, and success rates of the treatments. However, without more context or headings, it's difficult to provide a specific description of what the data represents or what medical condition is being treated.*
FDA Label Image

Figure-3 (Figure 2 Kaplan Meier Estimates Of Time To Progression Tamoxifen Study)

Figure-3 (Figure 2 Kaplan Meier Estimates Of Time To Progression Tamoxifen Study)
FDA Label Image

Figure-4 (Figure 3 Survival By Randomized Treatment Arm)

Figure-4 (Figure 3 Survival By Randomized Treatment Arm)
FDA Label Image

Figure-5 (Figure 4 Kaplan Meier Estimates Of Time To Progression Megestrol Acetate Study)

Figure-5 (Figure 4 Kaplan Meier Estimates Of Time To Progression Megestrol Acetate Study)
FDA Label Image

Figure-6 (Figure 5 Kaplan Meier Estimates Of Time To Progression Amino)

Figure-6 (Figure 5 Kaplan Meier Estimates Of Time To Progression Amino)
FDA Label Image

Figure 6

Figure 6
FDA Label Image

Figure-7 (Label)

Figure-7 (Label)
Each tablet of this medication contains 2.5 mg of Letrozole, USP. The usual dosage should be consulted in the package insert for complete prescribing information. It is recommended to keep this medication, along with all others, out of the reach of children and store it at room temperature between 20°C to 25°C (68°F to 77°F). The tablets are manufactured by Beijing Yiing Bio-engineering Technology Co., Ltd. and distributed by Yiling Pharmaceutical, Inc. located in Las Vegas, NV, USA. The tablets contain FDBC Yellow No.5 (tartrazine) as a color additive. This medication is prescription only and comes in a bottle of 30 tablets.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.